Product Description
| Cat Number | T3626 |
|---|---|
| Category | Biochemical |
| Pack Size | 1EA |
| Description | Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. |
| Molecular Weight | 465.51 |
| Purity | 0.9995 |
| Formula | C26H23N7O2 |
| Smiles | CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12 |
| Storage | -20 ℃ |
| View Document | |
| Note | This product is for Research Use Only |
Share Item: